

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

ATTORNEY DOCKET NO. CONFIRMATION NO. APPLICATION NO. FILING DATE FIRST NAMED INVENTOR 24747-1104US 09/17/2002 Travis Robert Glare 10/070,489 **EXAMINER** 03/08/2004 HELLER EHRMAN WHITE & MCAULIFFE LLP KUBELIK, ANNE R 4350 LA JOLLA VILLAGE DRIVE ART UNIT PAPER NUMBER 7TH FLOOR SAN DIEGO, CA 92122-1246

DATE MAILED: 03/08/2004

Please find below and/or attached an Office communication concerning this application or proceeding.



COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, DC 20231 www.uspto.gov

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
			EXAMINER

**ART UNIT** 

PAPER

304

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

## **Commissioner of Patents**

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

Specifically, there is no paper copy of the sequence listing.

Additionally, claims 22 and 23 are drawn to proteins of SEQ ID NO:1 or portions of SEQ ID NO1; however, SEQ ID NO:1 is an nucleotide sequence. These claims must be amended.

APPLICANT IS GIVEN 30 days FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R.. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anne R. Kubelik whose telephone number is (571) 272-0801. The examiner can normally be reached on Monday through Friday, 8:15 am -4:45 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amy Nelson, can be reached at (571) 272-0804. The fax number for the organization where this application or proceeding is assigned is (703) 872-9306. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 272-1600.

PATENT EXAMINER

	12				
	Application No.	Applicant(s)			
Notice to Comply	10/070,489 Examiner	GLARE ET AL.  Art Unit	<u> </u>		
NOTICE TO COMPLY WITH REQUIREMENT	Anne R. Kubelik	1638	INING		
NUCLEOTIDE SEQUENCE AND/OR AMINO			MINING		
Applicant must file the items indicated below within the avoid abandonment under 35 U.S.C. § 133 (extensions					
The nucleotide and/or amino acid sequence disclosure for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.		not comply with the	he requirements		
1. This application clearly fails to comply with the redirected to the final rulemaking notice published at the effective filing date is on or after July 1, 1998, set 1998) and 1211 OG 82 (June 23, 1998).	55 FR 18230 (May 1, 1990), and 1	114 OG 29 (May	15, 1990). If		
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).					
☐ 3. A copy of the "Sequence Listing" in computer rea 37 C.F.R. 1.821(e).	dable form has not been submitte	d as required by			
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."					
5. The computer readable form that has been filed unreadable as indicated on the attached CRF Diske submitted as required by 37 C.F.R. 1.825(d).					
☐ 6. The paper copy of the "Sequence Listing" is not to as required by 37 C.F.R. 1.821(e).	he same as the computer readabl	e from of the "Sec	juence Listing"		
☐ 7. Other:					
Applicant Must Provide:  ☐ An initial or substitute computer readable form (CRF	F) copy of the "Sequence Listing".		·		
An initial or substitute paper copy of the "Sequence specification.	Listing", as well as an amendmer	it directing its entr	y into the		
A statement that the content of the paper and component matter, as required by 37 C.F.R. 1.821(e) or 1.8			plicable, include		
For questions regarding compliance to these r	equirements, please contact	: :			
For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212 PatentIn Software Program Support	2				